Research programme: LFA-1 antagonists - Boehringer Ingelheim
Alternative Names: LFA-1 antagonists research programme - Boehringer IngelheimLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class Imidazolidines
- Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 15 Dec 2004 Preclinical trials in Autoimmune disorders in USA (unspecified route)